INDV Company Profile and Key Details

Indivior Pharmaceuticals Inc has 118.01 million shares outstanding. The public float is 116.04 million shares, elevated short interest at 10.95% of float. This equals 10.88 million shares. The short ratio is 7.11 days. Institutional investors hold 112.0% of the float. Insiders own 1.97%. Preblick Ryan holds 284.75 thousand shares, Heidbreder Christian has 209.34 thousand shares and Anderson Woodrow D has 27.64 thousand shares. Over the past six months, insider transactions show net selling. They sold 73.17 thousand shares across 3 transactions.

Indivior Pharmaceuticals Inc (NASDAQ:INDV) closed at $35.23 USD, gaining $0.35 (1.02%) from the previous close of $34.88. The stock is currently mid-range between its 52-week high and low $22.30 and $42.81. With a market capitalization of about $4.40 billion, Indivior Pharmaceuticals Inc is classified as a mid-cap and shows market-like volatility (beta ~1.11). Key stats such as the average daily volume over the past year has been around 2.13 million shares, volume is running light vs its 52-week average. Headquartered in North Chesterfield, VA, Indivior Pharmaceuticals Inc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Joseph J. Ciaffoni, the company employs approximately 833 people and listed since December 29, 2014. Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence.

Indivior Pharmaceuticals Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.25. This means the shares are trading below this model’s fair value.

Indivior Pharmaceuticals Inc trades at a P/E ratio of 12.28, slightly below the S&P 500 average, with a price-to-sales ratio of 3.27 and a price-to-book ratio of -21.02 indicating negative book value, which may reflect financial stress. The P/FCF stands at -39.21, also below market averages.

Our AI price prediction model suggests that Indivior Pharmaceuticals Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.23%, with price expected at $34.45 by October 02, 2026, within a range of $33.62 to $35.45 3-Month Outlook: Projected rise of 19.18%, reaching $41.57 by December 17, 2026, with a range of $41.18 to $41.97. 1-Year Outlook: Projected gain of 21.76%, with price at $42.47 by September 17, 2027, within a range of $39.27 to $45.52.

Indivior Pharmaceuticals Inc (NASDAQ:INDV) shares are flat -8.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Indivior Pharmaceuticals Inc trading at a premium to the broader market with a P/E of 12.28. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $28.60, suggesting -18.0% downside. Our AI forecast model points to short-term weakness (-1.23% over two weeks), a medium-term rise (19.18% over three months), and a longer-term gain (21.76% over one year), with expected trading ranges indicating moderate volatility.